Drug Profile
Research programme: retinoid-related orphan receptor antagonists - Bristol-Myers Squibb/Exelixis
Alternative Names: RORγ antagonists - Bristol-Myers Squibb/Exelixis; RORγ-t antagonists - Bristol-Myers Squibb/ExelixisLatest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Exelixis
- Developer Bristol-Myers Squibb; Exelixis
- Class Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for preclinical development in Inflammation in USA
- 13 Oct 2010 Early research in Inflammation in USA (unspecified route)